Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our lab in San Diego is looking for a motivated and enthusiastic candidate to support in vitro biochemical assay screening efforts. You will be producing biochemical activity & binding data using various technologies that will help drive rapid progress in our drug programs across a variety of different targets.

What you'll do

• Design and execute routine screening protocols from beginning to end using methods such as HTRF, FP, FI, and enzymatic assays.
• Routinely and independently analyze & QC experimental data.
• Program, validate, and operate liquid-handling automation (Biomek Liquid handler, Multidrop Combi, Integra Viaflo & Voyager) for 384-well plate-based assays and use instrumentation such as plate reader for reproducible, publication-quality data generation.
• Communicate results efficiently & precisely in written format by maintaining electronic lab notebook.

• B.S./M.S. in Biochemistry, Biology, or a related field with minimum 1 year of academic or industry lab experience.
• Ability to work efficiently and deliver results within timelines while maintaining a high attention to detail ensuring reliable and reproducible data generation.
• High attention to detail & excellent problem-solving skills.
• Experience with biochemical methods such as FP, TF-FRET, and enzymatic assays is preferred.
• Familiarity with lab automation/instrumentation is preferred.

• Competitive Pay
• Stock Option Eligibility
• 401(k) Plan
• Open PTO Policy
• Paid Company Holidays
• Free lunch and snacks at our offices
• Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees 

Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.

Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets. 

The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022, with a $20M upfront payment and a $670M total deal size), and Genentech (signed in 2020).

We raised a $200M series B in August 2023, and have raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. 

Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.

Finding the best talent is our top priority at Genesis Therapeutics. If you are interested in potential partnership on recruitment, please reach out to recruiting@genesistherapeutics.ai.